Insights into natriuretic peptides in heart failure: An update

Autor: Selma F. Mohammed, John C. Burnett, Guido Boerrigter, Josef Korinek
Rok vydání: 2008
Předmět:
Male
medicine.medical_specialty
Acute decompensated heart failure
medicine.drug_class
Volume overload
Pharmacology
Risk Assessment
Sensitivity and Specificity
Severity of Illness Index
Drug Administration Schedule
Renin-Angiotensin System
chemistry.chemical_compound
Physiology (medical)
Internal medicine
Natriuretic Peptide
Brain
Renin–angiotensin system
medicine
Natriuretic peptide
Humans
Natriuretic Peptides
Cyclic GMP
Cyclic guanosine monophosphate
health care economics and organizations
Randomized Controlled Trials as Topic
Heart Failure
Nesiritide
Dose-Response Relationship
Drug
business.industry
technology
industry
and agriculture
Natriuretic Peptide
C-Type
Prognosis
Brain natriuretic peptide
medicine.disease
Treatment Outcome
Endocrinology
chemistry
Heart failure
Acute Disease
Chronic Disease
Emergency Medicine
Drug Therapy
Combination
Female
Cardiology and Cardiovascular Medicine
business
medicine.drug
Zdroj: Current Heart Failure Reports. 5:97-104
ISSN: 1546-9549
1546-9530
DOI: 10.1007/s11897-008-0016-y
Popis: Natriuretic peptides (NPs) secreted by the heart in response to volume overload are pleiotropic molecules with vasodilating, diuretic, natriuretic, antiproliferative, and antifibrotic actions. Functioning of the NP system is altered in congestive heart failure (CHF), suggesting that support of the NP system might be beneficial in treatment of acute and chronic CHF. Several approaches alone or in combination with other pharmacologic therapies have been shown to enhance function of the NP system: direct administration of native and designer NPs, inhibition of degradation of NPs and their second messenger (cyclic guanosine monophosphate [cGMP]), and stimulation of cGMP generation. Despite increasing numbers of studies using NPs in therapy of acute and chronic CHF, several controversies regarding safety, efficacy, and dosing of NPs need to be addressed. Moreover, further research is warranted to identify the stages and etiologies of CHF that may profit from NP therapy.
Databáze: OpenAIRE
Externí odkaz: